Bristol-myers Squibb Compnay

Domantis Limited

Monsanto Technology LLC

Monsanto Company

Ecogen, Inc.

James William Bryson

Thomas M Malvar

Leigh H English

Michael A Von Tersch

Stephen L Slatin

Susan M Brussock

Caroline A Kulesza

Frederick S Walters

Aaron Paul Yamniuk

Suzanne J Suchard

Steven Grant

James K Tamura

Anish Suri

Philip Drew

Charles P Romano

Steven G Nadler

Olga Ignatovich

Robert P Rehfuss

Laura Price

Steven Sheriff

Stanley Krystek

James Tamura

Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single Vor Vdomain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.

Antibody polypeptides that antagonize CD40L

Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single Vor Vdomain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).

Methods of treating immune diseases by administering antibody polypeptides that antagonize CD40

Nucleic acids encoding antibody polypeptides that antagonize CD40

Methods of treating immune diseases by administering antibody polypeptides that specifically bind CD40L

Antibody polypeptides that antagonize CD40

Nucleic acids encoding antibody polypeptides that antagonize CD40L

Disclosed are nucleic acid segments comprising synthetically-modified genes encoding Coleopteran-toxic&#x3b4;-endotoxins. Also disclosed are methods of using these genes for the recombinant expression of polypeptides, the preparation of vectors containing the genes, and methods for transforming suitable host cells.

Coleopteran-resistant transgenic plants and methods of their production

The invention provides transgenic plants and transformed host cells which express modified cry 3B genes with enhanced toxicity to Coleopteran insects. Also disclosed are methods of making and using these transgenic plants, methods of making recombinant host cells expressing these &#x3b4;-endotoxins, and methods of killing insects such as Colorado potato beetle (Leptinotarsa decemlineata), southern corn rootworm (Diabrotica undecimpunctata howardi Barber) and western corn rootworm (Diabrotica virgifera virgifera LeConte.

Insect-resistant transgenic plants

Disclosed are nucleic acid segments comprising synthetically-modified genes encoding Coleopteran-toxic &dgr;-endotoxins. Also disclosed are methods of using these genes for the recombinant expression of polypeptides, the preparation of vectors containing the genes, and methods for transforming suitable host cells.

Nucleic acid compositions encoding modified Bacillus thuringiensis coleopteran-toxic crystal proteins

Disclosed are nucleic acid segments comprising synthetically-modified genes encoding modified Coleopteran-toxic Cry 3Bb* &dgr;-endotoxins. Also disclosed are methods of using these genes for preparing a Coleopteran-resistant transgenic plant and reducing insect in restations, and plants thereby produced.

Coleopteran-resistant transgenic plants and methods of their production using modified Bacillus thuringiensis Cry3Bb nucleic acids

Growing community of inventors

Langhorne, PA, United States of America

James William Bryson